Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by B52paulon Feb 17, 2021 2:55pm

196 Views

Post# 32586773

The database will be locked for analysis on March 5th

data audit from all sites and for all patients is now complete.
the Company will update the market on the final data release shortly after.

https://www.globenewswire.com/news-release/2021/02/17/2177029/0/en/Algernon-Pharmaceuticals-Provides-Update-on-COVID-19-Phase-2b-Final-Study-Data.html

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December